Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

On January 30, 2205 Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, reported that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time (Press release, Keros Therapeutics, JAN 30, 2025, View Source [SID1234649959]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat presentation will be available at
View Source and an archived replay will be accessible in the Investors section of the Keros website at View Source for up to 90 days following the conclusion of the event.

Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies

On January 30, 2025 Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, reported the company has been awarded $2.7 million in seed funding from CPRIT (Press release, Ypsilon Therapeutics, JAN 30, 2025, View Source [SID1234649975]). Ypsilon will use the grant to rapidly advance its lead therapeutic program, a next generation T-cell receptor mimic (TCRm) antibody, to drug candidate nomination, furthering its mission to deliver breakthrough treatments for patients with difficult to treat solid tumors such as triple negative breast cancer, non-small cell lung cancer, and gastric cancer. Ypsilon’s CPRIT grant, one of nine awards selected from 90 applicants, will also fund the critical establishment of the company’s operations in Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We founded Ypsilon to leverage the incredible specificity of how TCRs interact with proteins on the surface of cancer cells to enable new ways to target and treat cancer with high precision and efficacy"

TCRms are an emerging class of antibody-based drugs that have been engineered to bind with high specificity to intracellular protein fragments presented on the surface of cells by major histocompatibility complex molecules (pMHC). Compared to traditional antibodies that only target soluble or cell surface proteins, TCRms enable targeting of an expanded set of intracellular proteins including cancer testes antigens and other oncogenic drivers that are highly specific to tumor cells. Ypsilon is developing bispecific T cell engager molecules that can bind tumor associated pMHC complexes and drive potent cell killing.

"We founded Ypsilon to leverage the incredible specificity of how TCRs interact with proteins on the surface of cancer cells to enable new ways to target and treat cancer with high precision and efficacy," said Dr. Dongxing Zha, CEO/Co-Founder of Ypsilon and CTO of TCR Discovery and Engineering at Alloy. "The award from CPRIT will allow us to advance our lead TCRm program to drug candidate nomination and support our move to Texas, where I spent seven years of my career at the MD Anderson Cancer Center. I look forward to further contributing to the growth and success of the Texas biotech community."

Ypsilon’s innovative TCRm programs leverage Alloy’s Keyway TCR Discovery platform, which was developed by Dr. Zha. Alloy’s Keyway TCR Discovery platform is the first fully-integrated service offering to unlock the therapeutic potential of a variety of T-cell receptor-based modalities. Keyway’s end-to-end TCRm discovery service includes pMHC production, antibody discovery in Alloy’s suite of transgenic humanized mice, specificity screening, and generation of optimized T cell engagers. The combined support from CPRIT, 82VS, and Alloy Therapeutics strengthens the impact of Ypsilon’s research in addressing critical patients.

"The CPRIT grant is a significant endorsement of Ypsilon’s approach to developing novel cancer therapeutics and highlights 82VS’s ability to identify and launch companies with strong potential to secure external funding," said Errik Anderson, CEO and Founder of Alloy Therapeutics and General Partner at 82VS. "Ypsilon is leveraging the Keyway platform within Alloy, showcasing our commitment to democratizing access to advanced biologics discovery services and cutting-edge technologies. We’re confident that Ypsilon’s move to Texas will not only strengthen the state’s world-class biomedical community, but also enhance our ability to discover and support promising Texas-based companies through the 82VS portfolio."

Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers

On January 30, 2025 Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, reported that its RNA-targeting therapeutic, MABS-139, will be evaluated in pediatric cancer models through the National Cancer Institute (NCI) Pediatric Preclinical in Vivo Testing (PIVOT) Program (Press release, Manhattan BioSolutions, JAN 30, 2025, View Source [SID1234649960]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The PIVOT consortium, coordinated by The Jackson Laboratory, brings together leading pediatric cancer research centers to systematically evaluate promising therapies using extensively characterized patient-derived xenograft models. The studies with MABS-139 will be conducted at the University of Texas Health Science Center San Antonio, one of the PIVOT participating institutions. The collaboration, formalized through a Material Transfer Agreement with NCI, involves a two-phase research plan. In the first phase, PIVOT investigators will conduct tolerability study to confirm the dosing regimen. In the second phase, comprehensive efficacy testing will be conducted utilizing patient-derived xenograft models of pediatric cancers including Ewing sarcoma, malignant rhabdoid tumor, rhabdomyosarcoma, and hepatoblastoma. The research plan employs PIVOT’s innovative single mouse trial design to efficiently evaluate anti-tumor activity.

"Participation in the NCI PIVOT Program provides an extensive and invaluable level of expertise in preclinical pediatric cancer testing, and we are excited that MABS-139 was selected for evaluation after a diligent review process," said Dr. Borys Shor, CEO of Manhattan Bio. "Our novel agent degrades cancer-associated RNA which plays a fundamental role in promoting tumor growth, metastasis and resistance to current therapies. We are actively exploring this approach alongside other innovative payloads in our ADC development programs. This collaboration could potentially support a path to a rare disease pediatric voucher while generating valuable insights about addressing aggressive childhood cancers with limited treatment options."

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

On January 30, 2025 Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET (Press release, Mersana Therapeutics, JAN 30, 2025, View Source [SID1234649961]). A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share

On January 30, 2025 Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, reported financial results for the fourth quarter and full year ended December 31, 2024 (Press release, Quest Diagnostics, JAN 30, 2025, View Source [SID1234649962]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximately 5% organic growth, while also improving our profitability," said Jim Davis, Chairman, CEO, and President. "For the full year, we drove revenue growth of close to 7%, including approximately 3% from organic growth. Our team completed eight acquisitions, including LifeLabs in Canada, expanded our advanced diagnostics portfolio, and extended our geographic and market reach with new clinical, consumer and health plan customers."

Mr. Davis continued: "Our guidance for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024. These dynamics position us favorably to accelerate revenue and earnings growth in 2025."

Select 2024 full year accomplishments:

Completed eight acquisitions, including LifeLabs in Canada and four hospital outreach lab acquisitions.
Extended our health plan access to over 90% of in-network lives nationwide, including in new geographies through collaborations with Elevance Health and Sentara Health Plans, which took effect January 1, 2025.
Grew our Advanced Diagnostics portfolio, adding the sensitive p-tau217 and p-tau181 biomarkers to our AD-Detect blood-based test menu for assessing Alzheimer’s disease risk, and launching the first H5 avian influenza test from a commercial laboratory based on a pandemic preparedness contract from the U.S. Centers for Disease Control and Prevention.
Engaged approximately 75 academic, health system and community oncology centers in our Haystack MRD Early Experience Program, which provided oncologists with advanced access to our Haystack MRD blood test for aiding in the early detection of minimal residual disease from solid tumor cancers. We are now transitioning these organizations to a commercial program and are focused on expanding utilization among oncologists.
Expanded our questhealth.com consumer-initiated test platform to include approximately 135 tests, including micronutrient deficiencies and high-risk Lipoprotein(a) cholesterol testing.
Deployed automation and AI technologies across diverse laboratory, customer service and administrative areas, including automating core laboratory processes at three major regional laboratories, improving quality, customer experiences and productivity.

Three Months Ended December 31,

Twelve Months Ended December 31,

2024

2023

Change

2024

2023

Change

(dollars in millions, except per share data)

Reported:

Net revenues

$ 2,621

$ 2,288

14.5 %

$ 9,872

$ 9,252

6.7 %

Diagnostic information services revenues

$ 2,556

$ 2,221

15.1 %

$ 9,614

$ 8,976

7.1 %

Revenue per requisition

0.2 %

1.3 %

Requisition volume

13.9 %

5.5 %

Organic requisition volume

0.6 %

0.7 %

Operating income (a)

$ 361

$ 267

35.3 %

$ 1,346

$ 1,262

6.7 %

Operating income as a percentage of net revenues (a)

13.8 %

11.7 %

2.1 %

13.6 %

13.6 %

— %

Net income attributable to Quest Diagnostics (a)

$ 222

$ 192

15.1 %

$ 871

$ 854

2.0 %

Diluted EPS (a)

$ 1.95

$ 1.70

14.7 %

$ 7.69

$ 7.49

2.7 %

Cash provided by operations

$ 464

$ 527

(12.3) %

$ 1,334

$ 1,272

4.8 %

Capital expenditures

$ 123

$ 72

73.9 %

$ 425

$ 408

4.4 %

Adjusted (a):

Operating income

$ 409

$ 338

21.2 %

$ 1,541

$ 1,457

5.8 %

Operating income as a percentage of net revenues

15.6 %

14.8 %

0.8 %

15.6 %

15.8 %

(0.2) %

Net income attributable to Quest Diagnostics

$ 253

$ 245

3.7 %

$ 1,011

$ 994

1.8 %

Diluted EPS

$ 2.23

$ 2.15

3.7 %

$ 8.93

$ 8.71

2.5 %

(a)

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Dividend Increased

Quest Diagnostics’ Board of Directors has authorized a 6.7% increase in its quarterly dividend from $0.75 to $0.80 per share, or $3.20 per share annually, effective with the dividend payable on April 21, 2025 to shareholders of record of Quest Diagnostics common stock on April 7, 2025. The company has raised its dividend annually since 2011.

Guidance for Full Year 2025

The company estimates its full year 2025 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page of its investor relations website, which can be found at www.QuestDiagnostics.com/investor.

Low

High

Net revenues

$10.70 billion

$10.85 billion

Net revenues increase

8.4 %

9.9 %

Reported diluted EPS

$8.34

$8.59

Adjusted diluted EPS

$9.55

$9.80

Cash provided by operations

Approximately $1.45 billion

Capital expenditures

Approximately $500 million

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on January 30, 2025 until midnight Eastern Time on February 13, 2025, by phone at 866-360-8701 for domestic callers and 203-369-0179 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.